Showing 2171-2180 of 9245 results for "".
- FDA Seeks More Information on Pliaglishttps://practicaldermatology.com/news/20120419-fda_seeks_more_information_on_pliaglis/2459818/FDA's Complete Response Letter to Galderma Laboratories LP outlines additional information the FDA requires before it will approve the sNDA for Pliaglis, developer Nuvo Research, Inc. reports. The response is to the supplemental New Drug App
- Atlantic Dermatological Conference to be Held Next Monthhttps://practicaldermatology.com/news/20120320-atlantic_dermatological_conference_to_be_held_next__month/2459833/The 89th Atlantic Dermatological Conference hosted by the Dermatologic Society of Greater New York will be held April 27-29 at the Grand Hyatt Hotel, New York City. Register Online at DermSociety.org.
- Atlantic Dermatological Conference to be Held Next Monthhttps://practicaldermatology.com/news/20120320-atlantic_dermatological_conference_to_be_held_next__month/2459834/The 89th Atlantic Dermatological Conference hosted by the Dermatologic Society of Greater New York will be held April 27-29 at the Grand Hyatt Hotel, New York City. Register Online at DermSociety.org.
- Delicious Living magazine recognizes Wildly Natural Seaweed Body Creamhttps://practicaldermatology.com/news/20120229-delicious_living_magazine_recognizes_wildly_natural_seaweed_body_cream/2459862/The Delicious Living 2012 Beauty & Body Award for “Best New Product” went to The Seaweed Bath Co.'s Wildly Natural SeaweedTM Body Cream, the company announced. Delicious Living chose winners based on the products' efficacy without sacrificing purity, innovation and their dedication to raising standa
- FDA Grants Priority Review to Zasocitinib for Plaque Psoriasishttps://practicaldermatology.com/news/fda-grants-priority-review-to-zasocitinib-for-plaque-psoriasis/2488421/The US Food and Drug Administration (FDA) has accepted Takeda’s new drug application (NDA) for zasocitinib (TAK-279) for adults with moderate-to-severe plaque psoriasis and granted the application Priority Review, according to a company announcement.
- PISCES: Adalimumab Biosimilar Achieves PASI75 in 81% of Children With Severe Psoriasishttps://practicaldermatology.com/news/pisces-adalimumab-biosimilar-achieves-pasi75-in-81-of-children-with-severe-psoriasis/2488405/The first prospective study of an adalimumab biosimilar in Chinese children with severe plaque psoriasis showed significant clinical response through 16 weeks and no reported adverse events. The multicenter PISCES study, published in Dermatology and Therapy, included 80 patients a
- PCA SKIN Launches Acne Control Prebiotic Gel Cleanserhttps://practicaldermatology.com/news/pca-skin-launches-acne-control-prebiotic-gel-cleanser/2488391/PCA SKIN has launched Acne Control Prebiotic Gel Cleanser, a daily cleanser designed for acne-prone skin that pairs acne-fighting ingredients with technology intended to support the skin microbiome. The gel-to-lather cleanser contains 2% salicylic acid to help clear and prevent acne breako
- Consensus Statement: JAK Inhibitors Emerge as Primary Therapy for Severe Alopeciahttps://practicaldermatology.com/news/consensus-statement-jak-inhibitors-emerge-as-primary-therapy-for-severe-alopecia/2488332/A US expert consensus provides a standardized treatment framework for adults with severe alopecia areata (AA), placing oral Janus kinase (JAK) inhibitors at the center of long-term disease management.
- Review Integrates Functional and Aesthetic BTX-A Treatment for Facial Paralysishttps://practicaldermatology.com/news/review-integrates-functional-and-aesthetic-btx-a-treatment-for-facial-paralysis/2488325/Botulinum toxin A (BTX-A) may offer dermatologists a way to address the functional, therapeutic, and aesthetic manifestations of facial paralysis within a single treatment framework, a recent review suggested.d BTX-A Targets Multiple Sequelae of Facial Paralysis The authors conduc
- Daily SPF Use Lags Among Youth: Surveyhttps://practicaldermatology.com/news/daily-spf-use-lags-among-youth-in-multigenerational-skincare-survey/2488298/Interest in facial skincare is growing among children and adolescents, new findings suggest. Researchers evaluated a 3-product regimen consisting of a hydrating cream cleanser, hydrating moisturizer, and daily mineral SPF 40